Pfizer (NYSE:PFE) Hits New 52-Week High - What's Next?

Key Points

• Pfizer shares reached a new 52-week high of $29.09, supported by stronger-than-expected quarterly results and optimism that earnings can stabilize after the post-pandemic revenue decline.
• Pfizer settled more than 6,000 federal Depo-Provera lawsuits confidentially without admitting liability, removing a significant legal overhang. Oncology initiatives, including Padcev and pipeline candidate PF-08634404, remain central to the company’s long-term growth strategy.
• Analysts maintain a consensus “Hold” rating with an average price target of $28.28, while Pfizer offers a quarterly dividend of $0.43, equivalent to an annualized yield of about 6%.

Pfizer Inc. (NYSE:PFE - Get Free Report)'s share price reached a new 52-week high on Tuesday . The stock traded as high as $29.09 and last traded at $28.7470, with a volume of 8392245 shares trading hands. The stock had previously closed at $28.46.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reached a confidential settlement covering more than 6,000 federal lawsuits alleging that Depo-Provera was associated with intracranial meningioma. Although the financial terms were not disclosed and Pfizer admitted no liability, resolving the litigation removes a significant product-liability overhang and provides greater clarity for investors. Pfizer Reaches Confidential Settlement in Depo-Provera Litigation
• Positive Sentiment: Erste Group Bank raised its fiscal 2026 EPS estimate for Pfizer, reinforcing the view that earnings may stabilize or improve as the company manages the post-pandemic revenue decline. Pfizer FY2026 EPS Estimate Increased by Erste Group Bank
• Positive Sentiment: Pfizer’s oncology growth plans remain a key investment theme. Padcev is the current growth leader, while additional pipeline programs, including PF-08634404, and potential label expansions could support longer-term revenue growth and help offset pressure in other parts of the business. From Padcev to PF-08634404: Pfizer’s Oncology Growth Push
• Neutral Sentiment: Pfizer is being highlighted as a high-yield, defensive stock as some investors rotate toward dividend payers amid concerns about elevated technology and artificial-intelligence valuations. The income appeal may support demand, but it also reflects the company’s slower-growth profile. 3 Stocks for Investors Who Still Believe Cash Is King
• Negative Sentiment: Pfizer continues to trail the broader S&P 500 over the past year, highlighting ongoing investor concerns about muted growth, post-COVID revenue normalization and execution risk despite moderately positive analyst expectations. Is Pfizer Stock Underperforming the S&P 500?

Analysts Set New Price Targets

Several research analysts recently issued reports on PFE shares. Royal Bank Of Canada raised Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 price objective on the stock in a research note on Tuesday, June 9th. HSBC cut Pfizer from a "buy" rating to a "hold" rating and lowered their target price for the stock from $32.00 to $28.00 in a report on Monday, July 6th. Wall Street Zen raised Pfizer from a "hold" rating to a "buy" rating in a research report on Saturday, August 1st. Cantor Fitzgerald restated a "neutral" rating and set a $27.00 price target on shares of Pfizer in a research note on Monday, July 6th. Finally, Wolfe Research restated an "underperform" rating and issued a $26.00 price objective on shares of Pfizer in a report on Thursday, May 14th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $28.28.

Pfizer Price Performance

The firm has a market cap of $163.38 billion, a price-to-earnings ratio of 37.70 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The stock's 50 day simple moving average is $25.62 and its 200-day simple moving average is $26.30.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts' consensus estimates of $0.68 by $0.09. The company had revenue of $15.03 billion during the quarter, compared to analysts' expectations of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm's revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.0%. The ex-dividend date is Friday, July 24th. Pfizer's dividend payout ratio is currently 226.32%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Godfrey Financial Associates Inc. acquired a new position in Pfizer in the 4th quarter worth about $26,000. Keb Asset Management LLC acquired a new stake in Pfizer in the second quarter valued at approximately $26,000. Field & Main Bank purchased a new stake in shares of Pfizer in the second quarter valued at approximately $27,000. HFM Investment Advisors LLC raised its stake in shares of Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 427 shares during the period. Finally, Evolution Wealth Management Inc. raised its stake in shares of Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 566 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source